Search
MK-4830
go.drugbank.com/drugs/DB17454InvestigationalMK-4830 is a monoclonal antibody that targets the myeloid-specific immunoglobulin-like transcript (ILT) 4 receptor.
Ethinylestradiol
go.drugbank.com/drugs/DB00977ApprovedInvestigational[A191107] These properties were achieved by the substitution of an ethinyl group at carbon 17 of [estradiol].[A191107] Ethinylestradiol soon replaced [mestranol] in contraceptive pills. … Ethinylestradiol was first synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering.[A191107] It was developed in an effort to create an estrogen with greater oral bioavailability.
SC-236
go.drugbank.com/drugs/DB14059ExperimentalSC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) that has been studied in cancer therapy , lower back pain , and inflammation , , , .
MK-0752
go.drugbank.com/drugs/DB12852InvestigationalMk 0752 is under investigation in clinical trial NCT00572182 (MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer).
Aglatimagene besadenovec
go.drugbank.com/drugs/DB15074InvestigationalAglatimagene besadenovec is under investigation in clinical trial NCT00638612 (AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)).
Synonyms: ADV-TKPyridoxine
go.drugbank.com/drugs/DB00165ApprovedInvestigationalNutraceuticalVet approvedPyridoxine is the 4-methanol form of vitamin B6, an important water-soluble vitamin that is naturally present in many foods. As its classification as a vitamin implies, Vitamin B6 (and pyridoxine) are essential nutrients required for nor...
Mixtures: Pnv-VP-U, Folic-KBenznidazole
go.drugbank.com/drugs/DB11989ApprovedInvestigationalBenznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017.
Teclistamab
go.drugbank.com/drugs/DB16655ApprovedInvestigational[L43612] Teclistamab was later granted accelerated approval by the FDA on October 25, 2022.[L43617]
Ertugliflozin
go.drugbank.com/drugs/DB11827ApprovedInvestigational[A31581] Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.[L48621]
Phensuximide
go.drugbank.com/drugs/DB00832ApprovedThe frequency of attacks is reduced by depression of nerve transmission in the motor cortex.